

Supplementary Table 2. Baseline characteristics of patients according to the regimen changed at 12 months

Characteristic	Metformin+Empagliflozin (n=37)	Metformin+Sitagliptin (n=26)	Triple maintained (n=49) ^a	P value ^b
Body weight, kg	80.0±13.1	65.6±14.6	74.1±17.2	0.002
Body mass index, kg/m ²	27.4±3.7	23.3±4.2	26.3±4.5	0.001
Systolic blood pressure, mm Hg	131.2±10.9	128.1±15.0	133.5±16.6	0.358
Diastolic blood pressure, mm Hg	80.2±8.5	77.3±12.3	80.9±11.4	0.427
HbA1c, %	10.6±1.4	11.4±1.9	11.0±1.8	0.161
Fasting glucose, mg/dL	221.4±82.5	232.3±70.4	240.7±82.6	0.543
Total cholesterol, mg/dL	190.4±48.8	190.2±43.9	202.9±66.9	0.512
Triglycerides, mg/dL	151.5±69.9	149.2±108.5	203.0±221.0	0.240
HDL-C, mg/dL	44.4±8.3	51.8±15.3	50.3±12.6	0.033
LDL-C, mg/dL	116.0±36.1	115.5±33.9	123.3±46.7	0.636
Total ketone, μmol/L	623.1±1,251.8	458.7±663.9	662.9±1,657.0	0.836
Serum creatinine, mg/dL	0.82±0.17	0.76±0.21	0.78±0.20	0.448
eGFR-CKD-EPI, mL/min/1.73 m ²	100.0±16.7	99.5±13.9	100.2±18.5	0.985
Urinary protein/Cr ratio, mg/g	140.1±188.6	167.9±128.4	393.5±1,552.6	0.482
Uric acid, mg/dL	5.2±1.5	4.4±1.3	4.5±1.6	0.060
AST, IU/L	34.4±15.8	29.2±13.7	34.7±34.5	0.644
ALT, IU/L	46.8±27.6	31.8±24.2	41.7±46.3	0.276

Values are presented as mean ± standard deviation.

HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR-CKD-EPI, estimated glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration equation; Cr, creatinine; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

^aTriple: continuing metformin, sitagliptin, and Empagliflozin, ^bP values assessed by analysis of variance (ANOVA).